Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories orders, deals and press releases
601 filed, newest first. Page 12 of 13.
Apr 2009
22 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 22, 2009, titled "Dr. Reddy's launches Redispar (TM) in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
19 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 19, 2009, titled "Dr. Reddy's Laboratories realigns Global Generics geography portfolio". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 18, 2009, titled "Dr. Reddy's crosses $150 million revenue milestone in Russia & CIS region". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 12, 2009, titled "Dr. Reddy's receives favorable summary judgment ruling in the Omeprazole Mg OTC litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
5 Feb · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated February 05, 2009, titled "Dr. Reddy's announces five ANDA approvals and Generic product launches in the US Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
20 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 20, 2009, titled "Dr. Reddy's Q3 FY09 Revenue at Rs. 18,401 million, EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 02, 2009, titled "Dr Reddy's announces the appointment of new Chief Financial Officer (CFO)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
23 Dec · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated December 23, 2008, titled "Dr. Reddy's Laboratories announce settlement of Clarinex (R) (Desloratadine) ANDA patent litigation with Schering Corporation and Sepracor Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
24 Nov · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated November 24, 2008, titled "Dr. Reddy's launches authorized generic version of Imitrex Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
23 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on October 23, 2008 have, subject to such approvals as are required, approved a Scheme of Amalgamation by which Perlecan Pharma Private Limited, a subsidiary of the Company will be amalgamated with Dr Reddy's Laboratories Limited, effective January 01, 2006.23 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 23, 2008, titled "Dr. Reddy's Q2 FY09 Revenue at Rs. 16,151 million, EBITDA at Rs. 2,746 million, PAT at Rs. 1,212 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 14, 2008, titled "Dr. Reddy's wholly-owned subsidiary Promius Pharma launches EPICERAM (R) skin barrier emulsion ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
25 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 25, 2008, titled "Dr Reddy's enters the respiratory inhalers market in India with the launch of 'Combihale' and 'Redihaler' Forays into inhalation asthama market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 18, 2008, titled " Dr. Reddy's formally announces its US Specialty Business, Promius Pharma, LLC". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 04, 2008, titled "Dr Reddy's announces partnership with Cosmederm Technologies for Indian distribution of proprietary skin care products". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
30 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 30, 2008, titled "Dr. Reddy's Laboratories Limited invests in Perlecan Pharma Private Limited by acquiring shares of Joint Venture Partners". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 21, 2008, titled "Dr. Reddy'S Q1 FY09 Revenue at Rs.15,038 million; EBITDA at Rs.2,710 million, PAT at Rs. 1,346 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 18, 2008, titled "Dr. Reddy'S Annual Report on Form 20-F for the year ended March 31, 2008 available on the Company's website". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 08, 2008, titled "Dr Reddy's signs global distribution agreement with Albemarle Corporation for Ibuprofen API". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
29 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 29, 2008, titled "Dr Reddy's launches 'Atocor - R' - combination of Atorvastatin and Ramipril in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 22, 2008, titled "Dr Reddy's launches 'Omez Insta' - Immediate Release Omeprazole in sachets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 20, 2008, titled "Dr. Reddy's FY08 Revenue at Rs.50,006 million; EBITDA at Rs.9,736 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 01, 2008, titled "Dr. Reddy's announces the completion of two acquisitions". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
30 Apr · Business
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding a press release dated April 30, 2008, titled "Dr. Reddy's Acquires BASF's Pharmaceutical Contract Manufacturing Business and related facility at Shreveport in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 03, 2008, titled "Dr. Reddy's acquires Jet Generici Srl. Acquisition to establish Generics business in Italy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 01, 2008, titled "Dr. Reddy's signs definitive agreement to acquire Dowpharma Small Molecules business associated with Dow's Mirfield and Cambridge, UK Sites". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
10 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 10, 2008, titled "Dr. Reddy's Enters into Drug Discovery Collaboration with 7TM Pharma on Selected Drug Targets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
8 Feb · Business
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding a press release dated February 08, 2008, titled "Dr. Reddy's Announces collaboration with SkyePharma for New Product utilizing two of SkyePharma's proprietary drug delivery systems". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
25 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 25, 2008, titled "Dr. Reddy's Q3 FY08 Revenue at Rs 12,320 million; EBITDA at Rs 2,037 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "The Board of Directors of the Company has considered and approved raise of further equity by way of preferential issue of share warrants up to 5% of the existing equity of the Company exercisable into equal number of equity Shares of Rs.5 each to the promoters/ Promoter Group as per "Guidelines on Preferential Issues" under Chapter XIII of the SEBI (DIP) Guidelines, 2000, subject to the shareholders approval."21 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 21, 2008, titled "Dr. Reddy's announces settlement of Exelon(R) (rivastigmine tartrate) ANDA litigation with Novartis". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 16, 2008, titled "Dr. Reddy's launches Supanac(R) - (Diclofenac potassium)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2007
26 Nov · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated November 26, 2007 titled "Sygnis AG and DR.Reddy's Sign Exclusive Supply Collaboration for AX200 in Stroke". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Nov · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated November 26, 2007, titled "Argenta Discovery and Dr Reddy's progress pre-clinical anti-inflammatory candidate to treat chronic respiratory disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
24 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 24, 2007, titled "Dr. Reddy's Q2 FY08 revenue at Rs 12,670 million; Net Income at Rs 2,672 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.
Sep 2007
28 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 28, 2007, titled "Dr. Reddy's Annual Report on Form 20-F for year ended March 31, 2007 available on the Company's Website". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 28, 2007, titled "Dr. Reddy's commences operations in Philippines". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 13, 2007, titled "Dr. Reddy's receives USFDA approval for Ranitidine (Zantac TM) Tablets, 150mg (OTC)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 05, 2007, titled "Dr. Reddy's enters the Dermatology topical anti-fungal market with the launch of 'Ebernet TM'-(Eberconazole)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
1 Aug · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated August 01, 2007, titled "Rheoscience and Dr. Reddy's commence the first Phase III trial of Balaglitazone (DRF 2593)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
23 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 23, 2007, titled "Dr. Reddy's Q1 FY08 revenue at Rs 12,018 million; Net income at Rs 1,825 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 10, 2007, titled "Dr. Reddy's launches Glimy MP1 and Glimy MP2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
15 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 15, 2007, titled "Dr. Reddy's commences operations in Nigeria". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jun · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated June 08, 2007, titled "Dr. Reddy's enters the Dermatology topical steroid market with the launch of 'UltravexTM' - (Halobetasol)". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
18 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 18, 2007 , titled "Dr. Reddy's FY07 revenue at Rs.65,095 million (US$ 1.5 billion) Net Income at Rs. 9,327 million (US$ 216 million"". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
30 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 30, 2007, titled "Dr. Reddy's announces new R&D Chief". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 30, 2007, titled "Dr Reddy's launches Reditux(TM)- Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release, dated April 25, 2007, titled "Dr. Reddy's announces the launch of Zolpidem Tartrate tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release, dated April 24, 2007, titled "Dr. Reddy's employees awarded PG certificates from BITS Pilani." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release, dated April 17, 2007, titled "Dr. Reddy's is the first Participant in United States Pharmacopoeia's New Pharmaceutical Ingredient Verification Programme". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.